Influence of Pharmacist Intervention on Re-Elevation of Glycated Hemoglobin for Diabetic Outpatients

Takayoshi Maiguma1, Atsushi Komoto1, Emi Shiraga2

  • 1Shujitsu University, Okayama, Japan.

Hospital Pharmacy
|May 24, 2021
PubMed

Insights

Pharmacist intervention in clinics significantly improved blood sugar control in diabetic outpatients by reducing the average cumulative level of glycated hemoglobin (A1c) re-elevation (CARE). This intervention is valuable for preventing diabetes exacerbation.

Area of Science:

  • Endocrinology
  • Clinical Pharmacy
  • Public Health

Background:

  • Diabetes mellitus is a chronic condition requiring continuous management.
  • Elevated glycated hemoglobin (A1c) indicates poor glycemic control and increases complication risk.
  • Pharmacist-led interventions can enhance patient outcomes in chronic disease management.

Purpose of the Study:

  • To evaluate the impact of pharmacist intervention on glycemic control in diabetic outpatients.
  • To assess the effect of pharmacist intervention on the re-elevation of glycated hemoglobin (A1c) levels.
  • To determine if pharmacist intervention can prevent diabetes exacerbation.

Main Methods:

  • Retrospective chart review of 115 diabetic outpatients with A1c ≥7.5% from April 2014 to March 2016.
  • Comparison between a pharmacist intervention group (n=26) and a nonintervention group (n=89).
  • Analysis of average cumulative A1c re-elevation (CARE) and time to A1c re-elevation from baseline.

Main Results:

  • Pharmacist intervention group showed significantly lower CARE (0.89 ± 0.86%) compared to the nonintervention group (1.51 ± 1.25%, P = .0195).
  • No significant differences in CARE or time to re-elevation were observed based on baseline A1c severity (≥8.0% vs. 7.5-8.0%) or sex.
  • Time to A1c re-elevation from baseline did not differ significantly between groups.

Conclusions:

  • Pharmacist intervention in managed clinics significantly suppresses CARE in diabetic outpatients.
  • This intervention demonstrates potential utility in preventing the worsening of diabetes.
  • Pharmacist involvement is crucial for optimizing diabetes care and patient outcomes.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
316
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
661
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
498
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
383
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
345
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
345